NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs

Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program. ACD and its academic partner Cleveland Clinic will use the grant to develop and validate a diagnostic test based on ACD's proprietary RNAscope® technology for discriminating various B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.

"This award is a further validation of the clinical utility of RNAscope technology. We are very pleased that NCI has recognized the diagnostic potential of RNAscope technology and are grateful for its continued support", commented by Dr Yuling Luo, President and CEO of ACD.

Detection of B-cell clonality by demonstrating the restricted expression of one of the two immunoglobulin light chains (kappa or lambda) provides valuable molecular information for the diagnosis of NHLs. Formalin-fixed paraffin-embedded (FFPE) tissue is often the only sample type available for diagnostic testing in many clinical settings, however there has been a long-standing technical challenge in detecting light chain mRNAs in these tissues.

"In Phase I, we developed a manual RNAscope-based assay for light chain mRNAs and demonstrated that it allowed determination of light chain restriction in virtually all types of NHL using FFPE with 99% concordance with the current gold standard assay flow cytometry using fresh tissue", said Xiao-Jun Ma, Ph.D., ACD's Chief Scientific Officer, and Principal Investigator.

"This is an important advance in our ability to accurately diagnose B-cell lymphomas because conventional IHC (immunohistochemistry) and CISH (chromogenic in situ hybridization) methods to establish clonality simply don't work for the majority of NHLs for various reasons", said James Cook, M.D/Ph.D., hematopathologist and co-investigator at Cleveland Clinic.

The Phase II grant will develop a fully automated assay and advanced image analysis algorithms for objective interpretation to facilitate clinical adoption.

SOURCE Advanced Cell Diagnostics Inc. (ACD)

 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Advanced Cell Diagnostics. (2014, October 07). NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs. News-Medical. Retrieved on August 16, 2022 from https://www.news-medical.net/news/20141007/NCI-awards-2414M-grant-to-Advanced-Cell-Diagnostics-to-develop-diagnostic-test-for-B-cell-NHLs.aspx.

  • MLA

    Advanced Cell Diagnostics. "NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs". News-Medical. 16 August 2022. <https://www.news-medical.net/news/20141007/NCI-awards-2414M-grant-to-Advanced-Cell-Diagnostics-to-develop-diagnostic-test-for-B-cell-NHLs.aspx>.

  • Chicago

    Advanced Cell Diagnostics. "NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs". News-Medical. https://www.news-medical.net/news/20141007/NCI-awards-2414M-grant-to-Advanced-Cell-Diagnostics-to-develop-diagnostic-test-for-B-cell-NHLs.aspx. (accessed August 16, 2022).

  • Harvard

    Advanced Cell Diagnostics. 2014. NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs. News-Medical, viewed 16 August 2022, https://www.news-medical.net/news/20141007/NCI-awards-2414M-grant-to-Advanced-Cell-Diagnostics-to-develop-diagnostic-test-for-B-cell-NHLs.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
New generation of RNAscope products for RNA-biomarker analysis in FFPE tissue released